Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Industry experts predicts tough choices as NewJeans' ultimatum nears
-
6
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Opposition chief acquitted of instigating perjury
-
9
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
10
[Exclusive] Hyundai Mobis eyes closer ties with BYD
![[Exclusive] Hyundai Mobis eyes closer ties with BYD](//res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050044_0.jpg&u=)
![[Exclusive] Hyundai Mobis eyes closer ties with BYD](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=644&simg=/content/image/2024/11/25/20241125050044_0.jpg&u=)
2nd phase clinical trial of S. Korean drug firm's COVID-19 treatment candidate approved in US
By YonhapPublished : Nov. 30, 2020 - 10:34
South Korean drug firm GeneOne Life Science Inc. said Monday it has won approval to conduct a second phase clinical trial of its treatment candidate for the novel coronavirus in the United States.
The US Food and Drug Administration (FDA) have approved a phase two study of GLS-1027, an oral drug candidate known to prevent severe pneumonia caused by COVID-19 infection.
The candidate will be administered to 132 adult COVID-19 patients from the moment of their infection to evaluate the efficacy of preventing pneumonia, the company said.
GeneOne Life Science said that GLS-1027 significantly reduced levels of inflammatory cytokines resulting in pulmonary disease and lowered lung diseases in preclinical animal studies. (Yonhap)
The US Food and Drug Administration (FDA) have approved a phase two study of GLS-1027, an oral drug candidate known to prevent severe pneumonia caused by COVID-19 infection.
The candidate will be administered to 132 adult COVID-19 patients from the moment of their infection to evaluate the efficacy of preventing pneumonia, the company said.
GeneOne Life Science said that GLS-1027 significantly reduced levels of inflammatory cytokines resulting in pulmonary disease and lowered lung diseases in preclinical animal studies. (Yonhap)
